We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases.
Our Mission: To improve the lives of patients with cardiovascular and pulmonary diseases through the development of meaningful therapeutics
Our Pipeline: Our lead therapeutic candidate is FDA designated "Breakthrough" investigational CardiAMP™ Cell Therapy, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - ischemic heart failure (BCDA-01) and chronic myocardial ischemia (BCDA-02).
The Company’s second therapeutic platform, its NK1R+ MSC platform, an allogenic NK1 receptor positive mesenchymal stem cell population, an investigational culture expanded bone marrow derived allogenic or “off the shelf” cell therapy using neurokinin-1 receptor positive mesenchymal stem cells for the treatment of heart failure patients (BCDA-03) and acute respiratory distress syndrome (BCDA-04).
Empowered Patient Podcast
Henry Ford Health System
CALL US NOW
EMAIL US NOW